-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, OWGFBi6eEq+rf4bAjP6I+KvYwxuqoL+fVyj7ogG5t09vsnVzTJzqsIWXzUTbNO2L v6aYFtp4aeNNSVfKTdEBsA== 0000902561-04-000077.txt : 20040220 0000902561-04-000077.hdr.sgml : 20040220 20040220162359 ACCESSION NUMBER: 0000902561-04-000077 CONFORMED SUBMISSION TYPE: SC 13D/A PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20040220 SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: CARMIKE CINEMAS INC CENTRAL INDEX KEY: 0000799088 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-MOTION PICTURE THEATERS [7830] IRS NUMBER: 581469127 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13D/A SEC ACT: 1934 Act SEC FILE NUMBER: 005-37737 FILM NUMBER: 04619580 BUSINESS ADDRESS: STREET 1: 1301 FIRST AVE CITY: COLUMBUS STATE: GA ZIP: 31901 BUSINESS PHONE: 7065763400 MAIL ADDRESS: STREET 1: P O BOX 391 CITY: COLUMBUS STATE: GA ZIP: 31994 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: ZALAZNICK DAVID W CENTRAL INDEX KEY: 0001166818 FILING VALUES: FORM TYPE: SC 13D/A BUSINESS ADDRESS: STREET 1: 767 FIFTH AVENUE 48TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10153 BUSINESS PHONE: 2125720800 MAIL ADDRESS: STREET 1: 767 FIFTH AVENUE 48TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10153 SC 13D/A 1 sch13_bg022004.txt CARMIKE CINEMAS =============================================================================== SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D (Rule 13d-101) Under the Securities Exchange Act of 1934 (Amendment No. 1) CARMIKE CINEMAS, INC. - ------------------------------------------------------------------------------- (Name of Issuer) COMMON STOCK, $0.03 PAR VALUE - ------------------------------------------------------------------------------- (Title of class of securities) 143436400 - ------------------------------------------------------------------------------- (CUSIP number) DAVID W. ZALAZNICK 767 FIFTH AVENUE, 48TH FLOOR NEW YORK, NEW YORK 10153 - ------------------------------------------------------------------------------- (Name, address and telephone number of person authorized to receive notices and communications) JANUARY 29, 2004 - ------------------------------------------------------------------------------- (Date of event which requires filing of this statement) If the filing person has previously filed a statement on Schedule 13G to report the acquisition which is the subject of this Schedule 13D, and is filing this schedule because of Rule 13d-1(e), 13d-1(f) or 13d-1(g), check the following box [_]. Note: Schedules filed in paper format shall include a signed original and five copies of the Schedule, including all exhibits. The information required on the remainder of this cover page shall not be deemed to be "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act") or otherwise subject to the liabilities of that section of the Exchange Act but shall be subject to all other provisions of the Exchange Act. (Continued on following pages) (Page 1 of 9 pages) ================================================================================ - -------------------------------------------------------------------------------- CUSIP No. 143436400 13D - -------------------------------------------------------------------------------- - -------------------------------------------------------------------------------- 1 NAME OF REPORTING PERSON: David W. Zalaznick S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON: - -------------------------------------------------------------------------------- 2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP: (a) [_] (b) [x] - -------------------------------------------------------------------------------- 3 SEC USE ONLY - -------------------------------------------------------------------------------- 4 SOURCE OF FUNDS: N/A - -------------------------------------------------------------------------------- 5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) OR 2(e): [_] - -------------------------------------------------------------------------------- 6 CITIZENSHIP OR PLACE OF ORGANIZATION: United States - -------------------------------------------------------------------------------- NUMBER OF SHARES 7 SOLE VOTING POWER: 673,968 (see Items 5 and 6) - -------------------------------------------------------------------------------- BENEFICIALLY OWNED BY 8 SHARED VOTING POWER: -0- - -------------------------------------------------------------------------------- EACH REPORTING 9 SOLE DISPOSITIVE POWER: 673,968 (see Items 5 and 6) - -------------------------------------------------------------------------------- PERSON WITH 10 SHARED DISPOSITIVE POWER: -0- - -------------------------------------------------------------------------------- 11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY REPORTING PERSON: 673,968 (see Items 5 and 6) - -------------------------------------------------------------------------------- 12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES: [_] - -------------------------------------------------------------------------------- 13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11): 5.58% - -------------------------------------------------------------------------------- 14 TYPE OF REPORTING PERSON: IN - -------------------------------------------------------------------------------- Page 2 of 9 ITEM 1. SECURITY AND ISSUER. This Amendment No. 1 relates to the common stock, $0.03 par value per share, (the "Common Stock"), of Carmike Cinemas, Inc., a Delaware corporation (the "Company") and amends and supplements the Schedule 13D filed by the Beneficial Owners with the Securities and Exchange Commission (the "SEC") on February 11, 2002 (the "Schedule 13D"). The address of the principal executive office of the Company is 1301 First Avenue, Columbus, Georgia 31901. Capitalized terms used herein but not otherwised defined herein shall have the meanings ascribed to such terms in the Schedule 13D. ITEM 4. PURPOSE OF THE TRANSACTION. Item 4 is hereby amended by adding the following at the end thereof: On January 29, 2004, the Beneficial Owners entered into an Underwriting Agreement (the "Underwriting Agreement") with the Company, the other selling stockholders listed in Schedule II to the Underwriting Agreement (together with the Beneficial Owners, the "Selling Stockholders"), Goldman, Sachs & Co. ("Goldman Sachs"), as representative of the several underwriters listed in Schedule I to the Underwriting Agreement and UBS Securities LLC, as Independent Underwriter (collectively, the "Underwriters"). The Underwriting Agreement provides for purchases by the Underwriters (i) from the Company of 3,000,000 shares of Common Stock and (ii) from the Selling Stockholders of 1,850,000 shares of Common Stock (collectively, the "Initial Sale"). Of the 1,850,000 shares of Common Stock to be sold by the Selling Stockholders in the Initial Sale, the Beneficial Owners agreed to sell 171,240 shares. In addition, pursuant to the Underwriting Agreement, the Selling Stockholders granted the Underwriters an option, exercisable within 30 days after the date of the Underwriting Agreement, to purchase an additional 675,000 shares of Common Stock at the same purchase price per share for the purpose of covering over-allotments (the "Over-Allotment Option"). Of the 675,000 shares of Common Stock to be sold by the Selling Stockholders upon the exercise in full by the Underwriters of the Over-Allotment Option, the Beneficial Owners agreed to sell 84,912 shares. Pursuant to the final prospectus (the "Offering Prospectus") filed by the Company on January 30, 2004 (the "Offering Prospectus Date") pursuant to Rule 424 of the Securities Act of 1933 (as amended, the "Securities Act"), the public offering price in the public offering of Common Stock by the Company is $32.00 per share and the underwriting discount is $1.92 per share. Pursuant to the Underwriting Agreement, the Underwriters agreed to purchase shares of Common Stock in the Initial Sale and upon exercise of the Over-Allotment Option at a price per share of $30.08 (which is net of underwriting discounts and commissions). The Underwriting Agreement contains standard terms and conditions for a public offering including customary representations and warranties and indemnity provisions. The foregoing description of the Underwriting Agreement is not intended to be complete and is qualified in its entirety by the complete text of the Underwriting Agreement, a copy of which is filed as Exhibit 3 hereto. Page 3 of 9 Pursuant to the Underwriting Agreement, the Beneficial Owners agreed to sell 256,152 shares of Common Stock to the Underwriters, consisting of (i) 171,240 shares of Common Stock sold upon consummation of the Initial Sale and (ii) 84,912 shares of Common Stock sold upon exercise in full by the Underwriters of the Over-Allotment Option, in each case, at a price per share of $30.08 (which is net of underwriting discounts and commissions), for an aggregate amount of $7,705,052.16 (which consists of $5,150,899.20 received by the Beneficial Owners upon consummation of the Initial Sale and $2,554,152.96 received by the Beneficial Owners upon the Underwriters exercise the Over-Allotment Option in full). The consummation of the Initial Sale occurred on February 4, 2004 (the "Initial Sale Closing Date") and the consummation of the Over-Allotment Option occurred on February 11, 2004 (the "Over-Allotment Closing Date"). The Beneficial Owners may, from time to time, acquire additional shares of the Common Stock (subject to the availability of shares at prices deemed favorable by the Beneficial Owners), dispose of shares of Common Stock (subject to the transfer restrictions contained in the Stockholders Agreement described in Item 6 of the Schedule 13D), engage in discussions with other stockholders or third parties or some combination of the foregoing. Although the foregoing represents the possible activities presently contemplated by the Beneficial Owners with respect to the Company and the Common Stock, it should be noted that the possible activities of the Beneficial Owners are subject to change at any time and there is no assurance that the Beneficial Owners will actually undertake any of the foregoing. Additional information is included in the response to Item 6 of this Amendment No. 1 and Schedule 13D, which Item is incorporated herein by reference. Except as set forth above, the Beneficial Owners have no present plans or intentions which would result in or relate to any of the transactions described in subparagraphs (a) through (j) of Item 4 of Schedule 13D. ITEM 5. INTEREST IN SECURITIES OF THE ISSUER. (a) Based on information reported by the Company in the Offering Prospectus, after the consummation of the Initial Sale on February 4, 2004, there will be 12,088,512 shares of Common Stock outstanding as of the close of business on February 4, 2004 (the "Outstanding Shares") and the Beneficial Owners will beneficially own as of February 11, 2004, 673,968 shares of Common Stock representing approximately 5.58% of the Outstanding Shares. (b) Item 5(a) and Item 6 of this Amendment No. 1 and the Schedule 13D are incorporated herein by reference. By virtue of the Stockholders Agreement, the Beneficial Owners may be deemed to be part of a "group" for purposes of Section 13(d) Page 4 of 9 of the Act, whose members collectively hold more than 5% of the Company's Common Stock. Each Beneficial Owner disclaims its membership in such group and disclaims beneficial ownership of any shares of stock held by any Other Signatories attributed to them by reason of the Stockholders Agreement. The filing of this Schedule 13D shall not be construed as an admission that any Beneficial Owner is the beneficial owner of such shares or that the Beneficial Owners and any of such other stockholders constitute such a group or "person" for purposes of Section 13(d)(3) of the Act. (c) Except as set forth above, none of the Beneficial Owners, nor to the best of their knowledge, any of their executive officers or directors, has effected any transaction in any securities of the Company during the past 60 days. (d) Not applicable. (e) Not applicable. ITEM 6. CONTRACTS, ARRANGEMENTS, UNDERSTANDINGS OR RELATIONSHIPS WITH RESPECT TO SECURITIES OF THE ISSUER. Item 6 is hereby amended by adding the following at the end thereof: The responses set forth in Item 4 of this Amendment No. 1 and the Schedule 13D are incorporated herein by reference in their entirety. Lock-Up Agreement. In connection with the Initial Sale, the Company, its executive officers and directors and the Selling Stockholders have agreed not to offer, sell, contract to sell, pledge, grant any option to purchase, make any short sale or otherwise dispose of any shares of Common Stock, or any options or warrants to purchase any shares of Common Stock, or any securities convertible into, exchangeable for or that represent the right to receive shares of Common Stock, whether owned at the time of such agreement or acquired thereafter, owned directly by such person (including holding as a custodian) or with respect to which such person has beneficial ownership within the rules and regulations of the SEC during the period beginning from the Offering Prospectus Date and continuing to and including the date that is 165 days after the Offering Prospectus Date, without the prior written consent of Goldman Sachs as representative of the Underwriters (the "Lock-Up Agreement"). The foregoing description of the Lock-Up Agreement is not intended to be complete and is qualified in its entirety by the complete text of the Lock-Up Agreement, the form of which is filed as Exhibit 4 hereto. Letter Agreement. The Company and the Beneficial Owners entered into a letter agreement, dated November 17, 2003 (the "Letter Agreement"), pursuant to which, among other things, (i) each of the parties thereto agreed to waive the provisions of Section 3 of the Stockholders Agreement for purposes of the shares of Common Stock held by the Beneficial Owners to be sold in the proposed offering of the Company's Common Stock (the "Proposed Offering") pursuant to a registration statement on Form Page 5 of 9 S-1 (Commission File No. 333-90028) (the "Registration Statement"), (ii) each of the Beneficial Owners agreed to waive the requirement pursuant to Section 4(a) of the Registration Rights Agreement that it receive the 20-day advance written notice from the Company of the filing of the Registration Statement with respect to the Proposed Offering and (iii) the Company waived the requirement that each of the Beneficial Owners provide to the Company the written request pursuant to Section 4(a) of the Registration Rights Agreement with respect to the inclusion of shares of Common Stock held by such Beneficial Owners in the Proposed Offering. The foregoing description of the Letter Agreement is not intended to be complete and is qualified in its entirety by the complete text of the Letter Agreement, which is filed as Exhibit 5 hereto. Stockholders Agreement Amendment. The Company and the Beneficial Owners entered into the First Amendment to the Stockholders' Agreement, dated as of May 9, 2003 (the "Amendment"), pursuant to which, among other things, the parties thereto agreed to amend Sections 1.1(e) and 1.2 of the Stockholders Agreement. Section 1.1(e) of the Stockholders Agreement provided that the Beneficial Owners agree to vote their shares in a manner necessary to elect, among other persons, the following individual to the Company's Board of Directors: one (1) member of the Board of Directors, who shall be an Independent Director, designated from time to time in a writing delivered to the Company and signed by the CEO and approved by a majority of the members of the Board of Directors. The Amendment adds the following language to the end of Section 1.1(e) of the Stockholders Agreement: "provided that for purposes of the CEO designating any Board Designee pursuant to this Agreement, Mr. Roland C. Smith shall be deemed an Independent Director." Section 1.2 of the Stockholders Agreement provided that initially, the Company's Board of Directors shall consist of ten directors, at least three of whom shall be Independent Directors, and each director shall be designated as prescribed in Section 1.1 of the Stockholders Agreement. The Amendment replaces Section 1.2 of the Stockholders Agreement in its entirety with the following language: "Notwithstanding the foregoing, the Parties understand and agree that the Board of Directors may consist of up to twelve directors, ten of whom shall be designated as prescribed in Section 1.1 and two of whom may be elected according to the By-Laws. Three of the ten directors designated as prescribed in Section 1.1 shall be Independent Directors." The foregoing description of the Amendment is not intended to be complete and is qualified in its entirety by the complete text of the Amendment, which is filed as Exhibit 6 hereto Page 6 of 9 ITEM 7. MATERIAL TO BE FILED AS EXHIBITS. 3. Underwriting Agreement, dated January 29, 2004, by and among Carmike Cinemas, Inc., the Selling Stockholders listed in Schedule II thereto, Goldman, Sachs & Co., as representative of the several underwriters listed in Schedule I thereto, and UBS Securities LLC, as Independent Underwriter (filed as Exhibit 99.14 to Amendment No. 2 to the Schedule 13D of Goldman, Sachs & Co., et al, relating to the Company's Common Stock, filed on February 2, 2004 (the "Goldman, Sachs Schedule 13D").* 4. Form of Lock-Up Agreement (filed as Exhibit 99.15 to the Goldman, Sachs Schedule 13D).* 5. Letter Agreement, dated November 17, 2003 (filed as Exhibit 4.5 to the Company's Registration Statement on Amendment No. 2 to Form S-1 No. 333-90028).* 6. First Amendment to Stockholders' Agreement, dated as of May 9, 2003 (filed as Exhibit 4.4 to the Company's Registration Statement on Amendment No. 2 to Form S-1 No. 333-90028).* - --------------------------- * Incorporated herein by reference. Page 7 of 9 SIGNATURE After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. Dated: February 20, 2002 DAVID ZALAZNICK AND BARBARA ZALAZNICK, JT TEN /s/ David W. Zalaznick ----------------------------------- BY: DAVID W. ZALAZNICK Title: Joint Tenant /s/ Barbara Zalaznick ----------------------------------- BY: BARBARA ZALAZNICK Title: Joint Tenant Page 8 of 9 EXHIBIT INDEX EXHIBIT NO. DESCRIPTION PAGE NO. 3 Underwriting Agreement, dated January 29, 2004, * by and among Carmike Cinemas, Inc., the Selling Stockholders listed in Schedule II thereto, Goldman, Sachs & Co., as representative of the several underwriters listed in Schedule I thereto, and UBS Securities LLC, as Independent Underwriter (filed as Exhibit 99.14 to Amendment No. 2 to the Schedule 13D of Goldman, Sachs & Co., et al, relating to the Company's Common Stock, filed on February 2, 2004 (the "Goldman, Sachs Schedule 13D"). 4 Form of Lock-Up Agreement (filed as Exhibit 99.15 to * the Goldman, Sachs Schedule 13D). 5 Letter Agreement, dated November 17, 2003 (filed as * Exhibit 4.5 to the Company's Registration Statement on Amendment No. 2 to Form S-1 No. 333-90028). 6 First Amendment to Stockholders' Agreement, dated as * of May 9, 2003 (filed as Exhibit 4.4 to the Company's Registration Statement on Amendment No. 2 to Form S-1 No. 333-90028). - -------- * Incorporated herein by reference. Page 9 of 9 -----END PRIVACY-ENHANCED MESSAGE-----